Skip to main content
Top
Published in: Thyroid Research 1/2013

Open Access 01-12-2013 | Research

TSH receptor antibodies have predictive value for breast cancer – retrospective analysis

Authors: Paweł Szychta, Wojciech Szychta, Adam Gesing, Andrzej Lewiński, Małgorzata Karbownik-Lewińska

Published in: Thyroid Research | Issue 1/2013

Login to get access

Abstract

Background

Associations between breast cancer and thyroid disorders are reported in numerous studies. Relationships between thyroperoxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and breast cancer have been previously demonstrated. However, no analysis has been performed concerning an association between thyrotropin (TSH) receptor antibodies (TSHRAb) and breast cancer. The aim of the study was to evaluate the prevalence of breast cancer or benign breast tumors in patients with Graves’ disease and to analyze a possible relationship between Graves’ disease and these two groups of breast diseases with emphasis to epidemiology and laboratory findings.

Patients and methods

Clinical and laboratory details of 2003 women hospitalized for endocrine disorders were retrospectively analyzed, using an unpaired Student’s t-test, logistic regression analysis, χ2 test of independence or the two-sided ratio comparison test.

Results

The coexistence of Graves’ disease and breast cancer was statistically significant. We observed TSHRAb and TgAb more frequently in patients with breast cancer. We found that TSHRAb is the only variable possessing predictive value for breast cancer.

Conclusions

The strong relationship between Graves’ disease and breast cancer is proposed. We suggest that TSHRAb could be described as a positive determinant of breast cancer. The present data call attention to the usefulness of screening for breast cancer in long-term follow-up of patients with autoimmune thyroid disorders, especially of those with Graves’ disease. Similarly, screening for autoimmune thyroid disorders should be performed in patients with nodular breast disease. Additionally, the article draws ideas for further research in order to develop targeted treatment for more successful outcome in patients with breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dinda S, Sanchez A, Moudgil V: Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 2002, 21: 761–768. 10.1038/sj.onc.1205136PubMedCrossRef Dinda S, Sanchez A, Moudgil V: Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 2002, 21: 761–768. 10.1038/sj.onc.1205136PubMedCrossRef
2.
go back to reference Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI: Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 2006, 17: 60–64.PubMedCrossRef Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI: Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 2006, 17: 60–64.PubMedCrossRef
3.
go back to reference Turken O, NarIn Y, DemIrbas S, Onde ME, Sayan O, KandemIr EG, YaylacI M, Ozturk A: Breast cancer in association with thyroid disorders. Breast Cancer Res 2003, 5: R110-R113. 10.1186/bcr609PubMedCentralPubMedCrossRef Turken O, NarIn Y, DemIrbas S, Onde ME, Sayan O, KandemIr EG, YaylacI M, Ozturk A: Breast cancer in association with thyroid disorders. Breast Cancer Res 2003, 5: R110-R113. 10.1186/bcr609PubMedCentralPubMedCrossRef
4.
go back to reference Hellevik AI, Asvold BO, Bjøro T, Romundstad PR, Nilsen TI, Vatten LJ: Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009, 18: 570–574. 10.1158/1055-9965.EPI-08-0911PubMedCrossRef Hellevik AI, Asvold BO, Bjøro T, Romundstad PR, Nilsen TI, Vatten LJ: Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009, 18: 570–574. 10.1158/1055-9965.EPI-08-0911PubMedCrossRef
5.
go back to reference Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J: Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res 2010, 12: R33. 10.1186/bcr2587PubMedCentralPubMedCrossRef Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J: Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res 2010, 12: R33. 10.1186/bcr2587PubMedCentralPubMedCrossRef
6.
go back to reference Siegler JE, Li X, Jones SD, Kandil E: Early-onset breast cancer in a woman with Graves' disease. Int J Clin Exp Med 2012, 5: 358–362.PubMedCentralPubMed Siegler JE, Li X, Jones SD, Kandil E: Early-onset breast cancer in a woman with Graves' disease. Int J Clin Exp Med 2012, 5: 358–362.PubMedCentralPubMed
7.
go back to reference Angelousi AG, Anagnostou VK, Stamatakos MK, Georgiopoulos GA, Kontzoglou KC: Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis. Eur J Endocrinol 2012, 166: 373–381. 10.1530/EJE-11-0838PubMedCrossRef Angelousi AG, Anagnostou VK, Stamatakos MK, Georgiopoulos GA, Kontzoglou KC: Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis. Eur J Endocrinol 2012, 166: 373–381. 10.1530/EJE-11-0838PubMedCrossRef
8.
go back to reference Ito K, Maruchi N: Breast cancer in patients with Hashimoto’s thyroiditis. Lancet 1975, 2: 1119–1121.PubMedCrossRef Ito K, Maruchi N: Breast cancer in patients with Hashimoto’s thyroiditis. Lancet 1975, 2: 1119–1121.PubMedCrossRef
9.
go back to reference Kapdi JJ, Wolfe JN: Breast cancer relationship to thyroid supplements for hypothyroidism. JAMA 1976, 236: 1124–1127. 10.1001/jama.1976.03270110022020PubMedCrossRef Kapdi JJ, Wolfe JN: Breast cancer relationship to thyroid supplements for hypothyroidism. JAMA 1976, 236: 1124–1127. 10.1001/jama.1976.03270110022020PubMedCrossRef
10.
go back to reference Nelson M, Hercbergs A, Rybicki L, Strome M: Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132: 1041–1046. 10.1001/archotol.132.10.1041PubMedCrossRef Nelson M, Hercbergs A, Rybicki L, Strome M: Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132: 1041–1046. 10.1001/archotol.132.10.1041PubMedCrossRef
11.
go back to reference Maruchi N, Annegers JF, Kurland LT: Hashimoto’s thyroiditis and breast cancer. Mayo Clin Proc 1976, 51: 263–265.PubMed Maruchi N, Annegers JF, Kurland LT: Hashimoto’s thyroiditis and breast cancer. Mayo Clin Proc 1976, 51: 263–265.PubMed
12.
go back to reference Hamasaki H, Yoshimi T, Yanai H: A patient with Graves’ disease showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and thyroid stimulating antibody. Thyroid Res 2012, 5: 19. 10.1186/1756-6614-5-19PubMedCentralPubMedCrossRef Hamasaki H, Yoshimi T, Yanai H: A patient with Graves’ disease showing only psychiatric symptoms and negativity for both TSH receptor autoantibody and thyroid stimulating antibody. Thyroid Res 2012, 5: 19. 10.1186/1756-6614-5-19PubMedCentralPubMedCrossRef
13.
go back to reference Oh HJ, Chung JK, Kang JH, Kang WJ, Noh DY, Park IA, Jeong JM, Lee DS, Lee MC: The relationship between expression of the sodium/iodide symporter gene and the status of hormonal receptors in human breast cancer tissue. Cancer Res Treat 2005, 37: 247–250. 10.4143/crt.2005.37.4.247PubMedCentralPubMedCrossRef Oh HJ, Chung JK, Kang JH, Kang WJ, Noh DY, Park IA, Jeong JM, Lee DS, Lee MC: The relationship between expression of the sodium/iodide symporter gene and the status of hormonal receptors in human breast cancer tissue. Cancer Res Treat 2005, 37: 247–250. 10.4143/crt.2005.37.4.247PubMedCentralPubMedCrossRef
14.
go back to reference Munoz JM, Gorman CA, Elveback LR, Wentz JR: Incidence of malignant neoplasms of all types of patients with Graves' disease. Arch Intern Med 1978, 138: 944–947. 10.1001/archinte.1978.03630310034015PubMedCrossRef Munoz JM, Gorman CA, Elveback LR, Wentz JR: Incidence of malignant neoplasms of all types of patients with Graves' disease. Arch Intern Med 1978, 138: 944–947. 10.1001/archinte.1978.03630310034015PubMedCrossRef
15.
go back to reference Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, Sung FC, Cheng YH, Kao CH: Cancer risk in patients with Graves' disease: A nationwide cohort study. Thyroid in press Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, Sung FC, Cheng YH, Kao CH: Cancer risk in patients with Graves' disease: A nationwide cohort study. Thyroid in press
16.
go back to reference Hardefeldt PJ, Eslick GD, Edirimanne S: Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat 2012, 133: 1169–1177. 10.1007/s10549-012-2019-3PubMedCrossRef Hardefeldt PJ, Eslick GD, Edirimanne S: Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat 2012, 133: 1169–1177. 10.1007/s10549-012-2019-3PubMedCrossRef
17.
go back to reference Venturi S: Is there a role for iodine in breast diseases? Breast 2001, 10: 379–382. 10.1054/brst.2000.0267PubMedCrossRef Venturi S: Is there a role for iodine in breast diseases? Breast 2001, 10: 379–382. 10.1054/brst.2000.0267PubMedCrossRef
18.
go back to reference Jiskra J, Límanová Z, Barkmanová J, Smutek D, Friedmannová Z: Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol Res 2004, 53: 693–702.PubMed Jiskra J, Límanová Z, Barkmanová J, Smutek D, Friedmannová Z: Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol Res 2004, 53: 693–702.PubMed
20.
go back to reference Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F, Cecchetti D, Martino E, Pinchera A: Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 1996, 81: 990–994. 10.1210/jc.81.3.990PubMed Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F, Cecchetti D, Martino E, Pinchera A: Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 1996, 81: 990–994. 10.1210/jc.81.3.990PubMed
21.
go back to reference Smyth PPA, Shering S, Kilbane MT, Murray MJ, McDermott EWM, Smith DF, O’Higgins NJ: Serum thyroid peroxidase autoantibodies, thyroid volume and outcome in breast cancer. J Clin Endocrinol Metab 1998, 83: 2711–2716. 10.1210/jc.83.8.2711PubMed Smyth PPA, Shering S, Kilbane MT, Murray MJ, McDermott EWM, Smith DF, O’Higgins NJ: Serum thyroid peroxidase autoantibodies, thyroid volume and outcome in breast cancer. J Clin Endocrinol Metab 1998, 83: 2711–2716. 10.1210/jc.83.8.2711PubMed
22.
go back to reference Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW: Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005, 15: 1253–1259. 10.1089/thy.2005.15.1253PubMedCrossRef Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW: Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005, 15: 1253–1259. 10.1089/thy.2005.15.1253PubMedCrossRef
23.
go back to reference Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L, Burkman RT, Daling JR, Deapen D, Folger SG, Malone K, Marchbanks PA, McDonald JA, Strom BL, Wilson HG, Spirtas R: Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Prev 2002, 11: 1574–1578.PubMed Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L, Burkman RT, Daling JR, Deapen D, Folger SG, Malone K, Marchbanks PA, McDonald JA, Strom BL, Wilson HG, Spirtas R: Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Prev 2002, 11: 1574–1578.PubMed
24.
go back to reference Latif R, Morshed SA, Zaidi M, Davies TF: The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am 2009, 38: 319–341. 10.1016/j.ecl.2009.01.006PubMedCrossRef Latif R, Morshed SA, Zaidi M, Davies TF: The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol Metab Clin North Am 2009, 38: 319–341. 10.1016/j.ecl.2009.01.006PubMedCrossRef
25.
go back to reference Zygmunt A, Adamczewski Z, Wojciechowska-Durczyńska K, Cyniak-Magierska A, Krawczyk-Rusiecka K, Zygmunt A, Karbownik-Lewińska M, Lewiński A: Evaluation of efficacy of iodine prophylaxis in Poland based on the examination of schoolchildren living in Opoczno Town (Lodz Voivodship). Thyroid Res 2012, 5: 23. 10.1186/1756-6614-5-23PubMedCentralPubMedCrossRef Zygmunt A, Adamczewski Z, Wojciechowska-Durczyńska K, Cyniak-Magierska A, Krawczyk-Rusiecka K, Zygmunt A, Karbownik-Lewińska M, Lewiński A: Evaluation of efficacy of iodine prophylaxis in Poland based on the examination of schoolchildren living in Opoczno Town (Lodz Voivodship). Thyroid Res 2012, 5: 23. 10.1186/1756-6614-5-23PubMedCentralPubMedCrossRef
26.
go back to reference Mittra I, Perrin J, Kumaoka S: Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer. BMJ 1976, 1: 257–259. 10.1136/bmj.1.6004.257PubMedCentralPubMedCrossRef Mittra I, Perrin J, Kumaoka S: Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer. BMJ 1976, 1: 257–259. 10.1136/bmj.1.6004.257PubMedCentralPubMedCrossRef
27.
go back to reference Kilbane MT, Ajjan RA, Weetman AP, Dwyer R, McDermott EW, O'Higgins NJ, Smyth PP: Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab 2000, 85: 1245–1250. 10.1210/jc.85.3.1245PubMed Kilbane MT, Ajjan RA, Weetman AP, Dwyer R, McDermott EW, O'Higgins NJ, Smyth PP: Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab 2000, 85: 1245–1250. 10.1210/jc.85.3.1245PubMed
28.
go back to reference Beyer SJ, Jimenez RE, Shapiro CL, Cho JY, Jhiang SM: Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer? Breast Cancer Res Treat 2009, 115: 205–212. 10.1007/s10549-008-0059-5PubMedCentralPubMedCrossRef Beyer SJ, Jimenez RE, Shapiro CL, Cho JY, Jhiang SM: Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer? Breast Cancer Res Treat 2009, 115: 205–212. 10.1007/s10549-008-0059-5PubMedCentralPubMedCrossRef
29.
go back to reference Daniels GH, Haber DA: Will radioiodine be useful in treatment of breast cancer? Nat Med 2000, 6: 859–860. 10.1038/78604PubMedCrossRef Daniels GH, Haber DA: Will radioiodine be useful in treatment of breast cancer? Nat Med 2000, 6: 859–860. 10.1038/78604PubMedCrossRef
30.
go back to reference Boelaert K, Franklyn JA: Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet 2003, 361: 796–797. 10.1016/S0140-6736(03)12720-1PubMedCrossRef Boelaert K, Franklyn JA: Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers? Lancet 2003, 361: 796–797. 10.1016/S0140-6736(03)12720-1PubMedCrossRef
31.
go back to reference Dumont JE, Maenhaut C: Growth factors controlling the thyroid gland. Baillieres Clin Endocrinol Metabol 1991, 5: 727–753. 10.1016/S0950-351X(10)80012-6CrossRef Dumont JE, Maenhaut C: Growth factors controlling the thyroid gland. Baillieres Clin Endocrinol Metabol 1991, 5: 727–753. 10.1016/S0950-351X(10)80012-6CrossRef
32.
go back to reference Fernández-Soto ML, Jovanovic LG, González-Jiménez A, Lobón-Hernández JA, Escobar-Jiménez F, López-Cózar LN, Barredo-Acedo F, Campos-Pastor MM, López-Medina JA: Thyroid function during pregnancy and the postpartum period: iodine metabolism and disease states. Endocr Pract 1998, 4: 97–105. 10.4158/EP.4.2.97PubMedCrossRef Fernández-Soto ML, Jovanovic LG, González-Jiménez A, Lobón-Hernández JA, Escobar-Jiménez F, López-Cózar LN, Barredo-Acedo F, Campos-Pastor MM, López-Medina JA: Thyroid function during pregnancy and the postpartum period: iodine metabolism and disease states. Endocr Pract 1998, 4: 97–105. 10.4158/EP.4.2.97PubMedCrossRef
33.
go back to reference Karbownik-Lewińska M, Kokoszko-Bilska A: Oxidative damage to macromolecules in the thyroid - experimental evidence. Thyroid Res 2012, 5: 25. 10.1186/1756-6614-5-25PubMedCentralPubMedCrossRef Karbownik-Lewińska M, Kokoszko-Bilska A: Oxidative damage to macromolecules in the thyroid - experimental evidence. Thyroid Res 2012, 5: 25. 10.1186/1756-6614-5-25PubMedCentralPubMedCrossRef
34.
go back to reference Giustarini E, Pinchera A, Fierabracci P, Roncella M, Fustaino L, Mammoli C, Giani C: Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol 2006, 154: 645–649. 10.1530/eje.1.02108PubMedCrossRef Giustarini E, Pinchera A, Fierabracci P, Roncella M, Fustaino L, Mammoli C, Giani C: Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol 2006, 154: 645–649. 10.1530/eje.1.02108PubMedCrossRef
35.
go back to reference Ali A, Mir MR, Bashir S, Hassan T, Bhat SA: Relationship between the levels of Serum Thyroid Hormones and the Risk of Breast Cancer. J Biol Agr Healthc 2011, 2: 56–60. Ali A, Mir MR, Bashir S, Hassan T, Bhat SA: Relationship between the levels of Serum Thyroid Hormones and the Risk of Breast Cancer. J Biol Agr Healthc 2011, 2: 56–60.
36.
go back to reference Saraiva PP, Figueiredo NB, Padovani CR, Brentani MM, Nogueira CR: Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res 2005, 38: 761–765.PubMedCrossRef Saraiva PP, Figueiredo NB, Padovani CR, Brentani MM, Nogueira CR: Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res 2005, 38: 761–765.PubMedCrossRef
37.
go back to reference Smyth PPA: Autoimmune thyroid disease and breast cancer: a chance association. J Endocrinol Invest 2000, 23: 42–43.PubMedCrossRef Smyth PPA: Autoimmune thyroid disease and breast cancer: a chance association. J Endocrinol Invest 2000, 23: 42–43.PubMedCrossRef
38.
go back to reference Belkadi A, Jacques C, Savagner F, Malthièry Y: Phylogenetic analysis of the human thyroglobulin regions. Thyroid Res 2012, 5: 3. 10.1186/1756-6614-5-3PubMedCentralPubMedCrossRef Belkadi A, Jacques C, Savagner F, Malthièry Y: Phylogenetic analysis of the human thyroglobulin regions. Thyroid Res 2012, 5: 3. 10.1186/1756-6614-5-3PubMedCentralPubMedCrossRef
39.
go back to reference Cahoon EK, Rozhko A, Hatch M, Polyanskaya O, Ostroumova E, Tang M, Nadirov E, Yauseyenka V, Savasteeva I, McConnell RJ, Pfeiffer RM, Brenner AV: Factors associated with serum thyroglobulin levels in a population living in Belarus. Clin Endocrinol (Oxf) 2012. in press Cahoon EK, Rozhko A, Hatch M, Polyanskaya O, Ostroumova E, Tang M, Nadirov E, Yauseyenka V, Savasteeva I, McConnell RJ, Pfeiffer RM, Brenner AV: Factors associated with serum thyroglobulin levels in a population living in Belarus. Clin Endocrinol (Oxf) 2012. in press
40.
go back to reference Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA, for the PEDS-C Clinical Research Network: Autoantibodies and Autoimmune Disease During Treatment of Children With Chronic Hepatitis C. J Pediatr Gastroenterol Nutr 2013, 56: 304–310. 10.1097/MPG.0b013e3182774caePubMedCentralPubMedCrossRef Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA, for the PEDS-C Clinical Research Network: Autoantibodies and Autoimmune Disease During Treatment of Children With Chronic Hepatitis C. J Pediatr Gastroenterol Nutr 2013, 56: 304–310. 10.1097/MPG.0b013e3182774caePubMedCentralPubMedCrossRef
41.
go back to reference Hill OW: Thyroglobulin antibodies in 1,297 patients without thyroid disease. Br Med J 1961, 5242: 1793–1796.CrossRef Hill OW: Thyroglobulin antibodies in 1,297 patients without thyroid disease. Br Med J 1961, 5242: 1793–1796.CrossRef
42.
go back to reference Tunbridge WM, Vanderpump MP: Population screening for autoimmune thyroid disease. Endocrinol Metab Clin North Am 2000, 29: 239–253. 10.1016/S0889-8529(05)70129-8PubMedCrossRef Tunbridge WM, Vanderpump MP: Population screening for autoimmune thyroid disease. Endocrinol Metab Clin North Am 2000, 29: 239–253. 10.1016/S0889-8529(05)70129-8PubMedCrossRef
43.
go back to reference Mizia-Stec K, Zych F, Widala E: Mastopathy and simple goiter–mutual relationships. Przegl Lek 1998, 55: 250–258.PubMed Mizia-Stec K, Zych F, Widala E: Mastopathy and simple goiter–mutual relationships. Przegl Lek 1998, 55: 250–258.PubMed
44.
go back to reference Kopp P: The TSH receptor and its role in thyroid disease. Cell Mol Life Sci 2001, 58: 1301–1322. 10.1007/PL00000941PubMedCrossRef Kopp P: The TSH receptor and its role in thyroid disease. Cell Mol Life Sci 2001, 58: 1301–1322. 10.1007/PL00000941PubMedCrossRef
45.
47.
Metadata
Title
TSH receptor antibodies have predictive value for breast cancer – retrospective analysis
Authors
Paweł Szychta
Wojciech Szychta
Adam Gesing
Andrzej Lewiński
Małgorzata Karbownik-Lewińska
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Thyroid Research / Issue 1/2013
Electronic ISSN: 1756-6614
DOI
https://doi.org/10.1186/1756-6614-6-8

Other articles of this Issue 1/2013

Thyroid Research 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.